Therefore, several clinical trials had been developed to investigate the efficacy and safety of immune checkpoint inhibitors in patients with breast cancer, such as HER2 amplified tumor and triple negative breast cancer (TNBC). This evidence concerns the gene ERBB2 and breast carcinoma.